Login to Your Account

ViroPharma, Aventis Ending Deal For Picovir Development

By Randall Osborne

Friday, August 2, 2002
With news that its deal with Aventis Pharmaceuticals Inc. to develop Picovir (pleconaril) is being terminated by mutual agreement, ViroPharma Inc.'s stock took another trouncing - and the company disclosed plans to restructure, cutting its work force by 63 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription